AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT00235014
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 tablet QD
Trial: NCT04163185
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo tablet taken once upon the earliest onset of migraine pain.
Trial: NCT04369664
Drug: Statin
RxNorm normalized name: Statin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will be given up to 80 mg oral tablets daily for the entire study period preferably at the same time each day.
Trial: NCT02243436
Drug: Ara C
RxNorm normalized name: Toxocara cati Ab
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous use, 2g/m2, day 5
Trial: NCT00678132
Drug: AZD 2281
RxNorm normalized name: aspirin / hydrocodone bitartrate Oral Tablet [Azdone]
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00082511
Drug: Prasterone (GL701)
DrugBank: Prasterone sulfate (DB05804)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: There were 4 arms to the study:~During a previous 6 month db RCT, patients received either prasterone 200 mg/day or placebo. Upon entry into this open-label study, they were re-assigned by randomized allocation to receive either prasterone 200 mg/day or 100 mg/day. Hence, there were 4 possible treatment arms extending over the 18 months of observation between the double-blind study and the subsequent 12 month open-label extension study.
Trial: NCT03540615
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching placebo
Trial: NCT02024477
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 tablet daily for 12 weeks
Trial: NCT03695198
Drug: LY3361237 - SC
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LY3361237 administered SC
Trial: NCT03695198
Drug: LY3361237 - IV
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LY3361237 administered IV
Trial: NCT03695198
Drug: Placebo - SC
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo administered SC
Trial: NCT03695198
Drug: Placebo - IV
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo administered IV
Trial: NCT03053115
Drug: Liothyronine
RxNorm normalized name: Liothyronine
DrugBank: Liothyronine (DB00279)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cases will take liothyronine drops in the morning and two hours after dinner
Trial: NCT03053115
Drug: Placebos
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Controls will take placebo two hours after dinner
Trial: NCT02534753
Drug: Ascor L 500® (Ascorbic Acid Injection, USP)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A sterile, solution containing 500 mg ascorbic acid per mL
Trial: NCT01475344
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: intravenous infusion over 5 min/vial:~Body Weight: \< 30 kg / 30-60 kg / 60 - 90 kg / \> 90 kg~No. of vials: 1 vial (100 ml) / 2 vials (200 ml) / 3 vials (300 ml) / 4 vials (400 ml)~Placebo: 1.5 g / 3 g / 4.5 g / 6 g~Immediately after admission to hospital, the patient's parameters including blood collection (see below) will be measured for the second time (T2), if applicable, after the end of administration of the study drug. Additional measurements will be made 3 hours (T3), 9 hours (T4), and 24 hours (T5), 48 hours (T6) and one week after admission (T7). 30 days after inclusion in the study, a final investigation is planned (T8).
Trial: NCT00791102
Drug: Placebo for ASP-1001
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 sprays (total 200 microliters) in each nostril 20 minutes before allergen challenge.
Trial: NCT01026116
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 600 mg/m2 every-3-week for four cycles
Trial: NCT00689520
Drug: acenocoumarol
RxNorm normalized name: acenocoumarol
DrugBank: Acenocoumarol (DB01418)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: tinzaparin subcutaneously 175 IU anti-Xa/kg of body weight once daily for 7 days followed by acenocoumarol for 6 months
Trial: NCT04225247
Drug: Single Bond Universal
RxNorm normalized name: SKIN BOND
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single bond universal (by 3M ESPE) is a seventh generation bonding agents used as desensitizers in the present study.
Trial: NCT04712500
Drug: AND017
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AND017 oral capsule
Trial: NCT03456830
Drug: ALLN-177
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ALLN-177 7,500 units (2 capsules), orally, with each meal/snack, 3 to 5 times per day for 28 days
Trial: NCT03456830
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo 2 capsules, orally, with each meal/snack, 3 to 5 times per day for 28 days
Trial: NCT01039597
Drug: ORE1001
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral capsules containing 300 mg of the active, study drug
Trial: NCT01039597
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo capsules
Trial: NCT02228772
Drug: Doxorubicin
RxNorm normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Standard chemotherapy dosage and duration
Trial: NCT00834847
Drug: pravastatin
RxNorm normalized name: Pravastatin
DrugBank: Pravastatin (DB00175)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 40 mg tablet
Trial: NCT04297839
Drug: Control Group (heparin or continuous saline)
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Use of heparin in hemodialysis sessions. If there is any contraindication against the use of heparina, the investigators will perform saline flush of the dialysis system
Trial: NCT03287375
Drug: PIPAC
RxNorm normalized name: Zagam Respipac
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02669888
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Every 10 x 10 cm area of lesion requires 0.5 g of ointment, applied twice daily (morning and evening, separated by approximately 12±2 hours) for 6 weeks.
Trial: NCT00651300
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A single dose of IV saline (placebo) administered on Day 1 immediately before the surgical procedure as part of the Investigator's usual analgesic management practice, followed by oral doses of placebo (2 x matching valdecoxib 20 mg tablets) at 6-8 hours post-surgery on Day 1 and in the morning of Day 2 and Day 3
Trial: NCT00470418
Drug: NIC5-15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: a natural product, found in many foods and plants with mild insulin sensitizing effects
Trial: NCT00523692
Drug: depemedrone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: depomedrone (up to 120mg im/ia) methotrexate (added after symptoms have been present for 12 weeks)
Trial: NCT00490919
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: transdermal system (placebo) worn for 7 days
Trial: NCT00470418
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo comparator
Trial: NCT03711825
Drug: LYN-057
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administration of single dose of LYN-057 presented as extended release capsule containing 50 mg of memantine hydrochloride (HCl)
Trial: NCT02228772
Drug: Mercaptopurine
RxNorm normalized name: Mercaptopurine
DrugBank: Mercaptopurine (DB01033)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Standard chemotherapy dosage and duration
Trial: NCT02228772
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Standard chemotherapy dosage and duration
Trial: NCT02228772
Drug: Methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Standard chemotherapy dosage and duration
Trial: NCT03129360
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prepared in capsules to appear identical to levetiracetam.
Trial: NCT01014052
Drug: QLT091001
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral QLT091001 administered once daily for 7 days
Trial: NCT01955720
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01951599
Drug: AZD9291
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Volunteers will receive a single 20-mg dose of AZD9291 as a capsule on day 1, in Part A, Period 1, in the fasted state. (Treatment A).
Trial: NCT00545103
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo administered Once Daily (QD)
Trial: NCT00953940
Drug: Isotonic saline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Isotonic saline administrated i.v at 1.5 ml/Kg/h , 8 to 12 h before surgery
Trial: NCT01589263
Drug: onaBoNT-A + placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 U prostate injection once~Arms: ARM 1: onaBoNT-A + placebo
Trial: NCT03726125
Drug: LY3374849 - SC
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered SC
Trial: NCT03726125
Drug: LY3374849 - IV
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered IV
Trial: NCT01388088
Drug: Spironolactone
RxNorm normalized name: Spironolactone
DrugBank: Spironolactone (DB00421)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 25 mg twice a day
Trial: NCT01388088
Drug: Amiloride
RxNorm normalized name: Amiloride
DrugBank: Amiloride (DB00594)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 5 mg twice a day
Trial: NCT01388088
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: twice a day
Trial: NCT02040792
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02723279
Drug: TT
RxNorm normalized name: TTL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tolterodine tartrate (GSK， UK) 4mg per day is taken orally for six weeks
Trial: NCT01890902
Drug: Ketoprofen 10% Cream
RxNorm normalized name: KETOPROFEN 10% CREAM,TOP
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01890902
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03775278
Drug: PHP-303
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Investigational drug
Trial: NCT02382406
Drug: MK-3475 (Phase I)
RxNorm normalized name: vitamin MK 7
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MK-3475 2 mg/kg IV, D1 for 4 cycles (Cohort 1) or 3 cycles (Cohort 2) (cycle = 21 days)~Maintenance MK-3475 2 mg/kg IV continues every 21 days after Cycle 4 for up to 2 years.
Trial: NCT02382406
Drug: MK-3475 (Phase II)
RxNorm normalized name: vitamin MK 7
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MK-3475 200 mg IV Day 1 of each cycle (cycle = 21 days)~Maintenance MK-3475 2 mg/kg IV continues every 21 days after Cycle 4 for up to 2 years.
Trial: NCT01446042
Drug: Testosterone
RxNorm normalized name: Testosterone
DrugBank: (1,2,6,7-3H)Testosterone (DB14093)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intranasal testosterone
Trial: NCT02447380
Drug: AZD6094
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AZD6094 600MG qd
Trial: NCT02303639
Drug: Antiarrhythmic drug therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amiodarone (or sotalol) for prevention of VT/VF relapses
Trial: NCT02944526
Drug: Placebo - Concentrate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo suprascapular nerve block under ultrasound control: injection of 5ml physiological / isotonic saline
Trial: NCT02200029
Drug: Ademetionine IV+tablet
RxNorm normalized name: ademetionine
DrugBank: Ademetionine (DB00118)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IV ademetionine (500 mg/vial) for 2 weeks followed by oral ademetionine (500 mg/tablet, 2 in the morning and 1 before dinner) for 6 weeks
Trial: NCT02200029
Drug: Ademetionine tablet
RxNorm normalized name: ademetionine
DrugBank: Ademetionine (DB00118)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral ademetionine (500 mg/tablet, 2 in the morning and 1 before dinner) for 8 weeks
Trial: NCT00776984
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intervention = Randomisation: patient to receive double-blind treatment with either 5mcg/day tiotropium inhalation solution or placebo inhalation solution
Trial: NCT00661466
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo
Trial: NCT00274846
Drug: cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Days -5 and -4: 60 mg/kg
Trial: NCT03235037
Drug: Levodopa
RxNorm normalized name: Levodopa
DrugBank: Levodopa (DB01235)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: The target dose of Sinemet is 2-10 mg per kilogram per day of levodopa. The initial dose will be determined by your weight and age and will start at a low dosage level, 1 mg per kilogram per day. The dose will be re-evaluated after the first 2 weeks and may be adjusted at each visit depending on your response to the drug.
Trial: NCT01096160
Drug: MK-8226 BID, 1 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MK-8266 1 mg administered as oral capsules (0.7 mg + 0.3 mg), BID for 10 consecutive days. Panel A was completed prior to initiation of Panel B.
Trial: NCT01096160
Drug: MK-8266 BID, 1.8 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MK-8266 1.8 mg administered as oral capsules (1 mg + 0.8 mg), BID for 10 consecutive days. Panel B was completed prior to initiation of Panel C.
Trial: NCT01096160
Drug: MK-8266 TID, 1.8 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MK-8266 1.8 mg administered as oral capsules (0.6 mg), TID for 10 consecutive days. Panel C was completed prior to initiation of Panel D.
Trial: NCT01096160
Drug: MK-8266 TID, 2.4 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MK-8266 TID (Panel D), 2.4 mg administered as oral capsules (0.8 mg), TID for 10 consecutive days. Panel D was completed prior to initiation of Panel E.
Trial: NCT01096160
Drug: MK-8266 TID, 2.4 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MK-8266 TID (Panel E), 2.4 mg administered as oral capsules (0.8 mg), TID for 10 consecutive days. Panel E was initiated after completion of Panel D.
Trial: NCT01096160
Drug: Placebo BID (Panel A)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo administered as oral capsules BID for 10 consecutive days. Panel A was completed prior to initiation of Panel B.
Trial: NCT01096160
Drug: Placebo BID (Panel B)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo administered as oral capsules BID for 10 consecutive days. Panel B was completed prior to initiation of Panel C.
Trial: NCT01096160
Drug: Placebo TID (Panel C)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo administered as oral capsules TID for 10 consecutive days. Panel C was completed prior to initiation of Panel D.
Trial: NCT01096160
Drug: Placebo TID (Panel D)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo administered as oral capsules TID for 10 consecutive days. Panel D was completed prior to initiation of Panel E.
Trial: NCT01589380
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo was used in phase 3 clinical trial of fimasartan (NCT00922480, NCT01135212, and NCT01258673). The same placebo, which is manufactures at Boryoung pharmaceutical company, will be used in this trial. After enrollment and randomization, placebo will be administered one capsule once daily in placebo group.
Trial: NCT03331848
Drug: Placebo oral capsule
RxNorm normalized name: Placebo Oral Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BID
Trial: NCT03331848
Drug: PXT002331 - 20mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral
Trial: NCT04113941
Drug: Neuronox
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: intradetrusor injection
Trial: NCT04113941
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: intradetrusor injection
Trial: NCT02091414
Drug: corticosteroids
RxNorm normalized name: CORTICOSTEROIDS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: As per the practice of each participating center
Trial: NCT04978688
Drug: E2/NETA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered as an oral tablet once daily.
Trial: NCT02144038
Drug: LGH447
FDA approved: no
EMA approved: no
PMDA approved: no
Description: pan-PIM inhibitor
Trial: NCT02144038
Drug: BYL719
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PI3K-alpha inhibitor
Trial: NCT01854372
Drug: R-HCVAD and R-MC
RxNorm normalized name: pantolactone, (R)-
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01313299
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: I.M. (in the muscle) injection on day 1 of a single treatment cycle.
Trial: NCT04453761
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous NaCl0.9%
Trial: NCT02849509
Drug: Vitamin K antagonist
RxNorm normalized name: Vitamin K antagonists
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin K antagonist or Pradaxa
Trial: NCT02465944
Drug: FFP104
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Three intravenous infusions of FFP104 over 15 days (d0, d7 and d14)
Trial: NCT02465944
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Three intravenous infusions of 0.9% Saline over 15 days (d0, d7 and d14)
Trial: NCT01482871
Drug: ALG-1001
RxNorm normalized name: DRESSING,BIATAIN ALG 2IN X 2IN C#3705
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.5 mg per 100ul injected in the eye on day 0, day 30 and day 60 and followed for 180 days until unacceptable toxicity develops
Trial: NCT01482871
Drug: ALG-1001
RxNorm normalized name: DRESSING,BIATAIN ALG 2IN X 2IN C#3705
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2.5 mg per 100ul injected in the eye on day 0, day 30 and day 60 and followed for 180 days until unacceptable toxicity develops
Trial: NCT01482871
Drug: ALG-1001
RxNorm normalized name: DRESSING,BIATAIN ALG 2IN X 2IN C#3705
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5.0 mg per 100ul injected in the eye on day 0, day 30 and day 60 and followed for 180 days until unacceptable toxicity develops
Trial: NCT01482871
Drug: ALG-1001
RxNorm normalized name: DRESSING,BIATAIN ALG 2IN X 2IN C#3705
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 7.5 mg per 100ul injected in the eye on day 0, day 30 and day 60 and followed for 180 days until unacceptable toxicity develops
Trial: NCT02186977
Drug: 1.0 cc HBVAXPRO 10mcgr/ml (Sanofi Pasteur MSD)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.0 cc HBVAXPRO 10mcgr/ml (Sanofi Pasteur MSD)
Trial: NCT02186977
Drug: 0.1cc HBVAXPRO 40mcgr/ml (Sanofi Pasteur MSD)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.1cc HBVAXPRO 40mcgr/ml (Sanofi Pasteur MSD) with each injection
Trial: NCT00537186
Drug: Iron oligosaccharide
RxNorm normalized name: chitosan oligosaccharide
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00784719
Drug: CP-690,550
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ophthalmic topical solution, medium dose, dosed at least once/day, 8 weeks
Trial: NCT00784719
Drug: CP-690,550 Vehicle
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ophthalmic topical solution, dosed at least once/day, 8 weeks
Trial: NCT00908414
Drug: TMC589337 40 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive TMC589337 40 mg in Session Ia of Panel 1.
Trial: NCT00908414
Drug: TMC589337 100 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive TMC589337 100 mg in Session IIa of Panel 1.
Trial: NCT00908414
Drug: TMC589354 100 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive TMC589354 100 mg in Session IIb of Panel 2.
Trial: NCT00908414
Drug: TMC589354 400 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive TMC589354 400 mg in Session IVb of Panel 2.
Trial: NCT00908414
Drug: TMC589337 AA mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive TMC589337 AA mg on Days 1 to 7 in Session Va of Panel 3.
Trial: NCT00908414
Drug: TMC589337 EE mg
RxNorm normalized name: erythromycin
DrugBank: Erythromycin (DB00199)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Participants will receive TMC589337 EE mg on Days 1 to 7 in Session VII of Panel 7.
Trial: NCT00908414
Drug: TMC310911 600 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive TMC310911 600 mg in Panel 7.
Trial: NCT00908414
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive matching placebo to TMC589337 or TMC589354 in Panel 1 and 2.
Trial: NCT00023621
Drug: celecoxib
RxNorm normalized name: Celecoxib
DrugBank: Celecoxib (DB00482)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01948921
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01628783
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: once daily
Trial: NCT03138356
Drug: 2.5 mg ONGLYZA® (saxagliptin) tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Used in treatments C and F.
Trial: NCT03138356
Drug: 500 mg Glucophage XR®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Used in treatments C, F and I.
Trial: NCT02155985
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo for aspirin
Trial: NCT02998151
Drug: Lovastatin
RxNorm normalized name: Lovastatin
DrugBank: Lovastatin (DB00227)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: two 20mg pills
Trial: NCT02998151
Drug: Minocycline
RxNorm normalized name: Minocycline
DrugBank: Minocycline (DB01017)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: two 135mg pills
Trial: NCT02998151
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo pill